Alzheimer’s Drug Development Comparable To Cancer 50 Years Ago – Targacept CEO
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Developing drugs to effectively treat Alzheimer's disease has been stymied by a failure to understand underlying causes of the disease, according to industry panelists at the BioInvestor Forum in San Francisco
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class